Damora Therapeutics Inc (DMRA) FinancialsDMRADamora Therapeutics Inc

Evaluating the bottom line, Damora Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -132.85%, provide a clear picture of how effectively DMRA converts its operational activities into shareholder value.

In the context of the broader market, DMRA competes directly with industry leaders such as ORIC and LBRX. With a market capitalization of $1.16B, it holds a significant position in the sector. When comparing efficiency, DMRA's gross margin of N/A stands against ORIC's N/A and LBRX's N/A. Such benchmarking helps identify whether Damora Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Damora has been experiencing significant net losses, with a reported net income loss of $27.8 million in Q1 2026. However, its current ratio is strong at 22.48, indicating good short-term financial health. The company also has a price-to-book ratio of 2.46, which is reasonable for a biotech firm in its growth phase.